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Abstract
Apocynin has been widely used in vivo as a Nox2-contaninig nicotinamide adenine 
dinucleotide phosphate oxidase inhibitor. However, its time-dependent tissue distri-
bution and inhibition on organ reactive oxygen species (ROS) production remained 
unclear. In this study, we examined apocynin pharmacokinetics and pharmacodynam-
ics (PKPD) after intravenous (iv) injection (bolus, 5 mg/kg) of mice (CD1, 12-week). 
Apocynin was detected using a HPLC coupled to a linear ion-trap tandem mass 
spectrometer. Apocynin peak concentrations were detected in plasma at 1 minute 
(5494 ± 400 ng/mL) (t1/2 = 0.05 hours, clearance = 7.76 L/h/kg), in urine at 15 min-
utes (14 942 ± 5977 ng/mL), in liver at 5 minutes (2853 ± 35 ng/g), in heart at 5 min-
utes (3161 ± 309 ng/g) and in brain at 1 minute (4603 ± 208 ng/g) after iv injection. 
These were accompanied with reduction of ROS production in the liver, heart and 
brain homogenates. Diapocynin was not detected in these samples. Therapeutic ef-
fect	of	apocynin	was	examined	using	a	mouse	model	(C57BL/6J)	of	high-fat	diet	(HFD,	
16 weeks)-induced obesity and accelerated aging. Apocynin (5 mmol/L) was supplied 
in drinking water during the HFD period and was detected at the end of treatment in 
the brain (5369 ± 1612 ng/g), liver (4818 ± 1340 ng/g) and heart (1795 ± 1487 ng/g) 
along with significant reductions of ROS production in these organs. In conclusion, 
apocynin PKPD is characterized by a short half-life, rapid clearance, good distribution 
and inhibition of ROS production in major organs. Diapocynin is not a metabolite of 
apocynin in vivo. Apocynin crosses easily the blood-brain barrier and reduces brain 
oxidative stress associated with metabolic disorders and aging.
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1  | INTRODUC TION
Multiple organ oxidative stress attributable to increased reactive 
oxygen species (ROS) production plays an important role in the 
development of age-related metabolic, cardiovascular, and neu-
rodegenerative diseases.1,2 Although there are several enzymatic 
sources of ROS production in organs, a Nox2-containing nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase (Nox2) 
has been found to be an important source of increased ROS pro-
duction in these disease conditions.1,3-5 Under physiological condi-
tions, Nox2 is not activated and the low levels of ROS generated are 
mainly used for cellular signaling. However, Nox2 is activated under 
pathological conditions such as inflammation, metabolic disorders, 
ischemic reperfusion injury, and aging.1,4 Activated Nox2 generates 
large amount of O⋅−
2
 causing oxidative damage to tissues and organs. 
Knockout Nox2 protects cerebral vasculature and neurons from oxi-
dative damage and preserved locomotor function in aging mice.5
Apocynin (4-hydroxy-3-methoxyacetophenone) is a naturally oc-
curring compound isolated from the roots of Picrorhiza kurroa Royle 
ex Benth.6,7 It has a molecular weight of 166.17 Da, a pKa value of 
8.17 and a log P value (partitioning coefficient in n-octanol/water) of 
0.83, which give apocynin easy access to the cell membrane and its 
target sites.7 Apocynin acts by blocking p47phox (a major regulatory 
subunit of Nox2) forming a complex with cytochrome b, which inhibits 
O
⋅−
2
 production by Nox2 NADPH oxidase.6 Apocynin had been widely 
used as a Nox2 inhibitor in animal models of oxidative stress-related 
cardiovascular, metabolic, liver and neurodegenerative diseases.8-11 
However, there are discrepancies in the literature regarding the action 
of apocynin to reduce oxidative stress. For example, several studies had 
reported that diapocynin was a metabolite of apocynin, that apocynin 
acted through diapocynin.12,13 Others claimed that apocynin was an 
antioxidant rather than a Nox2 inhibitor in the vascular system since 
diapocynin was not formed in vascular endothelial cells or smooth mus-
cle cells.14 One study even found apocynin to promote ROS production 
in mouse embryonic cells.15 There has been a lack of pharmacokinet-
ics and pharmacodynamics (PKPD) characterization of apocynin as a 
Nox2 inhibitor to inhibit ROS production in major organs. No study had 
examined the ability of apocynin to cross blood-brain barrier (BBB) to 
reduce brain oxidative stress in disease conditions. Therefore, the ob-
jectives of the study were to establish in vivo the PK profile of apocynin 
in plasma, in urine and in major organs after iv injection and the PD 
profile of apocynin to inhibit O⋅−
2
 production in these organs.
In this study, we investigated the PKPD of apocynin in mice, which 
are the mostly used animals in experimental medicine. Time-dependent 
tissue distribution of apocynin in the plasma, urine, liver, heart, and 
brain was examined after intravenous (iv) injection and detected using 
a high-performance liquid chromatography (HPLC) coupled to a linear 
ion-trap tandem mass spectrometer (HPLC-MS/MS). PK simulation 
and	modeling	were	performed	using	Phoenix	WinNonlin	8.1	program.	
We	evaluated	the	time-dependent	 inhibitory	effects	of	apocynin	on	
ROS production by liver, heart, and brain tissues after iv injection. 
The therapeutic potential of apocynin in reducing major organ (heart, 
liver, and brain) oxidative stress was further examined using a mouse 
model of high fat-diet (HFD) induced obesity and accelerated aging.16 
The novel information provided by the current study helps the future 
application of apocynin or its derivatives as potential drugs to treat 
oxidative-stress-related diseases.
2  | MATERIAL S AND METHODS
2.1 | Chemicals and Reagents
Apocynin	 (purity	 ≥	 98%),	 diapocynin,	 and	 phenacetin	 (N-(4-
ethoxyphenyl) acetamide) (used as an internal stand for detec-
tion using HPLC-MS/MS) were obtained from Sigma Aldrich (UK). 
Methanol, water, acetonitrile of LC-MS grade, and ethanol of 
HPLC grade were purchased from Thermo Fisher Scientific, UK. 
Dihydroethidium (DHE) was from Invitrogen (UK). Antibodies against 
Nox2 were from Santa Cruz Biotechnology (UK). All other reagents 
were purchased from Sigma-Aldrich unless specified in the text.
2.2 | In vivo PKPD experiments and mouse model of 
high-fat diet-induced metabolic disorders
All studies were performed in accordance with the protocols ap-
proved by the Home Office under the Animals (Scientific Procedures) 
Act 1986, UK. For the PKPD study, male CD1 mice (Charles River 
Ltd) at 12 weeks of age with a body weight range between 25 and 
30 g were used for the study. Mice were fasted 12 hours before 
bolus iv injection of apocynin at 5 mg/kg body weight (dosing vol-
ume 5 mL/kg) via a lateral tail vein. Control mice were injected with 
vehicle (solvent of apocynin) at each time points. Four mice/per time 
points were sacrificed at 0, 1, 2.5, 5, 15, 30, 60 minutes and then 
at 3, 6, 12, and 24 hours after iv injection of apocynin. Blood sam-
ples were collected and centrifuged at 2000 g, 4°C for 10 minutes 
for plasma collection. Urine samples were collected from bladders. 
Tissues were harvested for further experiments.
The mouse model of high-fat diet (HFD-induced metabolic disor-
ders and accelerated aging was established as described previously.8 
Littermates	 of	 WT	 and	 Nox2KO	 mice	 (Jackson	 Laboratory)	 on	 a	
C57BL/6J	background	at	7	months	of	age	were	randomly	assigned	
(n =	6/per	group)	 to	a	HFD	containing	45%	kcal	 fat	 (Special	Diets	
Services),	or	to	a	normal	chow	diet	 (NCD)	containing	9.3%	kcal	fat	
(LabDiet Ltd) for 16 weeks. Apocynin was supplied in drinking water 
(5 mmol/L) for the treatment group. Body weights were measured 
weekly. Mice were sacrificed at 11 months of age and organs were 
harvested for further experiments.
2.3 | HPLC-MS/MS detection of apocynin, method 
validation, and sample extraction
The detection of apocynin in tissue sample was performed as de-
scribed previously with some modifications.17 In brief, apocynin was 
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detected using an Accela HPLC coupled to a linear ion-trap tandem 
mass spectrometry (LTQ-Orbitrap XL; Thermo-Fisher Scientific) 
(HPLC-MS/MS) in the negative ion mode. Phenacetin (500 ng/mL) 
was used as an internal standard in every vial. A reversed-phase 
50 × 2.1 mm ID, 1.9 mm particle, 175 Å pore C18 Hypersil Gold col-
umn (Thermo Scientific) was used with injection volume set at 5 µL 
for the separation of apocynin and phenacetin. Calibration curve 
used for PK analysis was constructed by spiking apocynin in mouse 
plasma using eight calibrators ranging from 1 to 10000 ng/mL 
with great reproducibility and R2	≥	0.996	for	subsequent	5	separate	
experiments on different days. Best fit curve was achieved using 
linear regression model (1/ꭓ2 weighting factor) which showed mini-
mum percentage relative error. Limit of detection for apocynin was 
set	up	at	 signal	 to	noise	 ratio	≥	3,18 which is 1 ng/mL in our sys-
tem. The limitation of quantification was set up at signal to noise 
ratio	≥	10,	which	 is	10	ng/mL	 in	our	system.	Orbitrap	component	
was used for the full scan spectra of apocynin and diapocynin.
2.4 | PK simulation and model analysis using 
Phoenix WinNonlin 8.1
PK parameters simulation was performed using the Phoenix 
WinNonlin	8.1	software	(Certa	ra.com).	The	values	of	plasma	apoc-
ynin concentrations vs actual sampling time (1-30 minutes) after iv 
injection were modeled by non-compartmental analysis.19,20 The 
calculated parameters included peak concentration (Cmax); AUC1-
30 min and AUC0-∞ (time 0 to infinity); elimination rate constant 
(kel), t1/2, and plasma clearance (CL). Data collected from sampling 
time 1-360 minutes after iv injection were then pooled (n = 3) 
and tested against various compartmental models for a best fit 
using	Phoenix	WinNonlin	8.1	software.	Parameters	 included	 the	
Akaike's information criterion (AIC), Bayesian information crite-
ria (BIC) and corrected AIC (AICc) calculated using the equation: 
AICc = AIC +2 × nParm (nParm +	1)/(nObs	−	nParm	−	1).
21
2.5 | LogBB calculation
LogBB of apocynin was calculated as described previously22 using 
the equation: LogBB = Log (Cbrain/Cplasma).	 We	 used	 the	 values	
from 1 to 30 minutes detected in both plasma and brain tissues for 
LogBB calculation since apocynin plasma concentration was fallen 
to ~10 ng/mL (limit of quantification) after 30 minutes of iv injection, 
n = 3 mice/per time point.
2.6 | Measuring ROS production
ROS production was measured using tissue homogenates 
by three complementary techniques: lucigenin (5 µmol/L)-
chemiluminescence (Molecular Devices); DHE (2 µmol/L) fluores-
cence on brain tissue sections, and brain tissue lipid peroxidation 
by malondialdehyde (MDA) assay as described previously.5 The 
specificity of detection of O⋅−
2
 was confirmed by adding tiron 
(10 mmol/L), a non-enzymatic O⋅−
2
 scavenger. The enzymatic 
sources of O⋅−
2
 production were identified using inhibitors tar-
geting nitric oxide synthase (L-NG-Nitro arginine methyl ester, 
L-NAME, 100 μmol/L), the mitochondrial complex-1 enzymes (ro-
tenone, 50 μmol/L), xanthine oxidase (oxypurinol, 250 μmol/L), 
flavo-proteins (diphenyleneiodonium, DPI, 20 μmol/L), or superox-
ide dismutase (SOD) (200 U/mL). The DHE fluorescence was cap-
tured using a Nikon fluorescence microscope (Eclipse Ti2-E). The 
fluorescence intensity was quantified from at least three random 
images per section with three sections/per sample.
2.7 | Mouse model of HFD-induced metabolic 
disorder and aging
The HFD study was performed exactly as described previously.8 
Littermates	 of	WT	 and	 Nox2KO	mice	 on	 a	 C57BL/6J	 background	
(Jackson	Laboratory,	USA)	were	bred	in	our	institution	from	heterozy-
gotes and genotyped. Male mice at 7 months of age were randomly as-
signed (n =	6/per	group)	to	a	HFD:	45%	kcal	fat,	20%	kcal	protein	and	
35%	kcal	carbohydrate	(Special	Diets	Services),	or	a	NCD:	9.3%	kcal	
fat,	25.9%	kcal	protein,	and	64.8%	kcal	carbohydrate	(LabDiet	Ltd)	for	
16 weeks. Apocynin was supplied in drinking water (5 mmol/L). Body 
weights were measured weekly. Mice (at 11 months) were fasted 
8 hours before being sacrificed by an overdose of pentobarbital. The 
body weights were recorded and organs were harvested.
2.8 | Immunofluorescence microscopy
The experiments were performed exactly as described previously.23 
Midbrain (containing hippocampus and ventral tegmental area re-
gions) cryosections were used for the experiments. Primary anti-
bodies	were	used	at	1:250	dilution.	Bovine	serum	albumin	(2%)	was	
used in the place of primary antibodies as a negative control. Biotin-
conjugated secondary antibody was used at 1:1000 dilution. Specific 
binding of antibodies was detected by streptavidin-Cy3. Images 
were captured using a Nikon fluorescence microscope (Eclipse Ti2-
E). Fluorescence intensities were quantified as described above.
2.9 | Data analysis
For the in vivo PKPD, three mice were used for each time point and 
a total of 8 time points were used at 0, 1, 2.5, 5, 15, 30, 60, and 
180 minutes after iv injection of apocynin. Data were expressed as 
the means ± SD unless otherwise specified in the figure legends. 
For the HFD study, six mice were used for each group. Statistical 
analysis was performed using one-way ANOVA, followed by 
Bonferroni post hoc tests. P < .05 was considered statistically 
significant.
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3  | RESULTS
3.1 | Detection of apocynin and diapocynin in 
tissues after IV bolus injection
Full scan of apocynin and diapocynin were performed using 
LTQ Orbitrap mass spectrometry under the negative heated 
electrospray ionisation mode. Apocynin was detected as a promi-
nent peak at m/z 165.0543 and diapocynin was detected as a 
prominent peak at m/z 329.1058 (Figure S1). Apocynin (500 ng/
mL) spiked in mouse plasma was then used as control for the de-
tection using HPLC-MS/MS, which showed a prominent single 
symmetrical peak appeared at a retention time of approximately 
5.5-5.7 minutes. Apocynin was detected in the plasma, urine, and 
F I G U R E  1  Representative chromatograms of apocynin detected 
using HPLC-MS/MS. Control sample (top panel) was apocynin 
(500 ng/mL) spiked into mouse plasma and was detected as a 
prominent peak at ~5.5-5.7 min. Apocynin was detected in the plasma, 
brain, liver, and heart samples harvested at 5 min and in urine samples 
harvested at 15 min after intravenous injection. HPLC-MS/MS, HPLC 
coupled to a quadrupole-linear ion-trap tandem mass spectrometry
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the tissue homogenates of the brain, liver, and heart after iv bolus 
injection (Figure 1).
Apocynin had been reported to form diapocynin, in the presence 
of H2O2 and myeloperoxidase, in order to be active.
14 Therefore, we 
examined the formation of diapocynin in the samples of apocynin 
using HPLC-MS/MS (Figure 2). The control was diapocynin (500 ng/
mL) spiked in mouse plasma, which showed a clean single symmet-
rical peak appeared at a retention time of approximately 7 minutes. 
However, diapocynin was not detected in our samples of plasma, 
brain, and liver homogenates after iv bolus injection of apocynin. 
Our data showed clearly that diapocynin is not a metabolite of 
apocynin in vivo.
3.2 | Time-dependent distribution of apocynin in 
tissues and PK simulation
Time-dependent (up to 24h) tissue distributions of apocynin after 
iv injection were depicted in Figure 3. Apocynin was detected in 
the plasma with a concentration of 5494 ± 400 ng/mL at 1 min-
ute, 3237 ± 1560 ng/mL at 5 minutes, ~50 ng/mL at 15 minutes 
and then fallen to ~10 ng/mL at 30 minutes after iv injection 
(Figure 3A). Apocynin was undetectable in the urine until 5 min-
utes after injection. Urine apocynin concentration reached peak 
(20492 ng/mL) at 30 minutes, and reduced to 230 ± 31 ng/mL at 
3 hours after injection and remained detectable up to 12 hours 
F I G U R E  3   Pharmacokinetic profile of 
apocynin post intravenous bolus (5 mg/
kg) in different tissues. (A) Plasma, (B) 
Urine, (C) liver, (D) Heart, and (E) Brain. 
Left panels showed PK profiles from 
time 1-180 min; Right panels showed PK 
profiles from 3-24 h. Data were presented 
as Mean ± SD. n = 3 mice per time point
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(Figure 3B). Apocynin was detected in the brain tissues with 
a concentration of 4603 ± 208 ng/g of tissue weight at 1 min-
ute and reduced to 103 ± 4 ng/g at 30 minutes after iv injection 
(Figure 3C). Apocynin was detected in the liver with a peak con-
centration of 2853 ± 35 ng/g tissue weight at 5 minutes after 
injection (Figure 3D). Apocynin was detected in the heart with a 
peak concentration of 3161 ± 309 ng/g tissue weight at 5 minutes 
after injection (Figure 3E).
The PK values of apocynin (1-30 minutes) fits well with the 
linear regression model of log(time)-concentration data (R2	≥.93)	
and	were	 simulated	 using	 the	 Phoenix	WinNonlin	 8.1	 non-com-
partmental analysis model (Table 1). The central volume of dis-
tribution (Vd) was 568.74 mL/kg. The Cmax was 5494 ng/mL. 
Apocynin displayed rapid elimination (t1/2 = 0.05 hours) and 
systemic clearance (CL = 7.76 L/h/kg). Data collected at sam-
pling time (1-360 minutes) were used to fit into compartmental 
models	in	WinNonlin	(Table	1).	The	smaller	AIC	and	BIC	values	of	
the compartmental analysis indicate a better fit for the concen-
tration-time profile. However, when the sample number is small 
(n < 40), the smallest AICc should be used to predict the best fit 
for the model.24 Apocynin PK profile fitted better into the one 
compartmental model with the smallest values of AIC, AICc and 
BIC, 378.5, 379.7, and 382.4, respectively, in comparison to the 
values obtained for two and three compartment models.
3.3 | Pharmacodynamic investigation of apocynin 
on reducing organ ROS production
The time-dependent effects of apocynin on the levels of organ 
O
⋅−
2
 production was examined by lucigenin-chemiluminescence 
(Figure 4). The representative examples of real-time recordings of 
O
⋅−
2
 production in samples collected at 15 minutes after iv injection 
were shown on the left panels, and the PD profiles of apocynin ef-
fects on tissue O⋅−
2
 production were shown on the right panels. Tiron 
(an O⋅−
2
 scavenger) was used to confirm the assay specificity.
In vehicle injected control mice, the levels of tissue O⋅−
2
 produc-
tion remained the same overtime (Figure S2). Compared to control 
TA B L E  1  Pharmacokinetic	parameters	of	apocynin	simulated	using	WinNonlin	8.1	software	(n	=	3)
Pharmacokinetic parameters Units NCA
Time point: 0-6 h
1-CA 2-CA 3-CA
C0 ng/mL 7359.89 — — —
Cmax ng/mL 5494.00 — — —
AUC0-30min ng/mL/h 643.47 — — —
AUC0-∞ ng/mL/h 644.27 681.33 711.10 711.07
t1/2 h 0.05 — — —
Kel 1/h 13.65 — — —
CL mL/h/kg 7760.69 — — —
tvCL1 mL/h — 5541.14 5540.91 5521.18
tvCL2 mL/h — — 0.17 4.03
tvCL3 mL/h — — — 16.45
Vd mL/kg 568.74 — — —
tvV1 mL — 530.72 530.72 530.71
tvV2 mL — — 0.37 63.99
tvV3 mL — — — 51.90
LogLik — — −186.25 −186.25 −186.25
−2LL — — 372.50 372.50 372.50
AIC — — 378.50 382.50 386.50
AICc — — 379.70 385.84 393.50
BIC — — 382.04 388.39 394.75
nParm — — 3 5 7
nObs — — 24 24 24
Abbreviations: 1-CA, 2-CA or 3-CA, one, two or three compartmental analysis (values were from 0 to 6 h); AIC, Akaike information criterion; AICc, 
AIC corrected; AUC0-30 min, Area under the curve from time 0 to 30 min; AUC0-∞, Area under the curve from time 0 extrapolated to infinite time; BIC, 
Bayesian information criterion; C0, extrapolated plasma concentration at time 0; CL, clearance; Cmax, maximum plasma concentration; Kel, elimination 
rate constant; LogLik, log likelihood; NCA, non-compartmental analysis (values were from 0 to 30 min, R2 = .93); nObs, number of observations; 
nPharm, number of PK parameters; t1/2, terminal half-life; tvCL1, tvCL2 or tvCL3, typical value (tv) of one, two and three compartmental clearance; 
tvV1, tvV2 or tvV3, typical value (tv) of one, two or three compartmental volume of distribution; Vd, volume of distribution.
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F I G U R E  4   Pharmacodynamic profile of apocynin on inhibiting the levels of reactive oxygen species (ROS) production by major organs. 
(A) liver, (B) heart, and (C-F) brain. A-C, O⋅−
2
 production in tissue homogenates measured by lucigenin-chemiluminescence. Left panels: 
Representative kinetic detection of O⋅−
2
 production in samples collected at 15 min after apocynin intravenous (iv) injection. Controls were 
tissue samples without apocynin injection. Right panels: Time course (0-360 min). n = 3 mice per time point. D, Levels of lipid peroxidation in 
brain tissues detected by malondialdehyde (MDA) assay. E, In situ ROS production detected by dihydroethidium (DHE) fluorescence on brain 
sections at 15 min after iv injection of apocynin. Control samples were brain section of mice without apocynin. Tiron was used to confirm 
the detection of O⋅−
2
. F, LogBB of apocynin after iv injection. Data were presented as Mean ± SD. n = 3 mice per time point
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samples (without apocynin, at time 0), apocynin inhibited the liver 
O
⋅−
2
 production within 1 minute, lasted for ~60 minutes and the 
effect disappeared at 3 hours after iv injection (Figure 4A, right 
panel). Apocynin inhibited the levels of heart O⋅−
2
 production start-
ing at 1 minute, becoming significant at 2.5 minutes, lasting for 
~60 minutes and the inhibitory effect disappeared at 3 hours after 
iv injection (Figure 4B, right panel). Apocynin inhibited brain O⋅−
2
 
production (60.4 ±	25.4%)	starting	at	1	minute,	becoming	signif-
icant at 2.5 minutes, lasting up to 60 minutes and the inhibitory 
effect disappeared at 3 hours after iv injection (Figure 4C, right 
panel). Although the PK distributions were similar in these tissues, 
the PD profile of apocynin were different, which was due to the 
difference in Nox2 expression and activities. In the heart homog-
enates, most proteins were from cardiomyocytes where Nox2 
expression/mg protein is relatively low. However, Nox2 is highly 
expressed in microglial cells, in brain microvascular system, and in 
neurons.
As an independent approach, the time-dependent inhibitory 
effect of apocynin on brain ROS production was further examined 
by the levels of lipid peroxidation using an MDA assay (Figure 4D), 
which	showed	a	similar	pattern	of	 inhibition	by	apocynin.	We	also	
examined the in situ ROS production using DHE fluorescence on 
brain sections harvested at 15 minutes after iv injection (Figure 4E). 
Apocynin inhibited effectively the DHE fluorescence on brain 
sections.
LogBB is defined as a reliable index of drug permeability of the 
BBB to reach the central nerve system (CNS).22,25 If Log BB value is 
≥0.3,	it	indicates	the	drug	has	readily	crossed	BBB	and	entered	the	
CNS; and if the value is <−1,	it	suggests	that	the	drug	is	poorly	dis-
tributed to the brain.25	Apocynin	had	a	LogBB	value	between	−0.1	
(at 1 minute) and 1 (at 30 minutes) (Figure 4F), which indicated that 
apocynin could easily cross the BBB and enter the CNS.
3.4 | Effect of apocynin on reducing organ oxidative 
stress-associated with metabolic disorders and aging
The therapeutic potential of apocynin on reducing major organ 
oxidative stress associated with metabolic disorders and aging was 
examined using a mouse model of HFD-induced obesity and ac-
celerated aging (Figure 5). Apocynin was supplied in drinking water 
(5 mmol/L) throughout the 16 weeks of HFD period. Mice were 
sacrificed at 11 months of age. Compared to controls, HFD mice 
(without apocynin treatment) had a massive increase in body weight 
and this was significantly reduced in the apocynin treatment group 
(Figure 5A). Apocynin was detected by HPLC-MS/MS in major or-
gans, that is, brain (5369 ± 1612 ng/g), liver (4818 ± 1340 ng/g), 
and heart (1795 ± 1487 ng/g) at the end of treatment (Figure 5B). 
These data further demonstrated that apocynin (oral application) 
penetrated easily through the BBB with a concentration in the brain 
similar to the concentration detected in the liver.
The effect of apocynin on reducing HFD-induced major 
organ oxidative stress was examined using lucigenin-chemilu-
minescence (Figure 5C-E). SOD was used to confirm the assay 
specificity. Representative real-time recordings of O⋅−
2
 produc-
tion detected in livers, hearts, and brains were shown in the left 
panels, and the statistical analysis (n = 6 mice) were given in the 
right panels of Figure 5C-E. Compared to the levels of O⋅−
2
 de-
tected	 in	 control	 samples	 (expressed	 as	 100%),	 HFD	 increased	
significantly the levels of O⋅−
2
 production in the livers (Figure 5C), 
hearts (Figure 5D) and brains (Figure 5E). The effect of apocynin 
treatment on brain Nox2 expression was examined by immuno-
fluorescence on brain sections (Figure 6). Compared to control 
samples, the level of Nox2 expression was increased markedly in 
the HFD brain sections and this was significantly reduced after 
apocynin treatment.
4  | DISCUSSION
Apocynin has emerged as a promising inhibitor of Nox2 NADPH 
oxidase used for animal models of human oxidative-stress related 
diseases.8,9,11,26 However, there were discrepancies in the litera-
ture regarding the way that apocynin reduces ROS production 
in cells and in tissues, and no study had investigated its PKPD 
profiles in major tissues. The current study by investigating apo-
cynin PKPD in mice demonstrated, for the first time, that apoc-
ynin after iv injection was distributed quickly into major organs, 
that is, heart, liver, and the brain and inhibited ROS production in 
these	organs.	We	provided	the	evidence	that	apocynin	can	readily	
cross	BBB	with	logBB	values	between	−0.04	and	1	and	inhibited	
effectively brain ROS production. More importantly, we demon-
strated, using a mouse model of HFD-induced obesity and acceler-
ated aging, the therapeutic potential of apocynin in reducing major 
organ oxidative stress under these disease conditions. Diapocynin 
was not detected in any of our samples after iv injection, which 
supported the notion that diapocynin is not a metabolite of apo-
cynin in vivo.17,27
Linear ion-trap tandem mass spectrometer methodology had 
been employed for the quantification of apocynin in plasma and 
tissue samples.17 However, the retention time of apocynin de-
tected in this previous report was extremely short (0.45-0.50 min-
utes), leaving people questioning if the analyte used in that study 
had been retained and separated enough to achieve a convincing 
F I G U R E  5   Effect of apocynin on reducing major organ (liver, heart, and brain) oxidative stress associated with dietary obesity and 
accelerated aging in mice. Apocynin was supplied in drinking water during high-fat diet (HFD) period. A, Changes in bodyweight. B, Apocynin 
detected in tissue homogenates by HPLC-MS/MS after treatment. C-E, The levels of O⋅−
2
 production in tissue homogenates detected by 
lucigenin-chemiluminescence. Left panels: Representative kinetic detection of O⋅−
2
 production. Right panels: Statistical analysis. Data were 
presented	as	%	of	NCD	(100%).	n	= 6 mice/group. *P < .05 for indicated values vs NCD values. †P < .05 for indicated values vs HFD values. 
HPLC-MS/MS, HPLC coupled to a quadrupole-linear ion-trap tandem mass spectrometry; NCD, normal chow diet
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result. In addition, the starting time point of sampling was 5 min-
utes after iv injection, which missed the crucial time points for ac-
curate PK assessment of a small cell membrane permeable chemical, 
like apocynin.17 Compared to this previous report, the HPLC-MS/
MS method used in the current study has the following advantages. 
(a) a later retention time that demonstrated actual interaction with 
the stationary phase; (b) a neat and sharp chromatographic peak 
for quantification; (c) a reasonably high level of sensitivity to detect 
apocynin	to	a	concentration	as	low	as	1	ng/mL.	We	applied	sampling	
time point of 1, 2.5 and 5 minutes, which covered the short half-life 
of apocynin (t1/2 = 0.05 hours) following iv administration and pro-
vided accurate PKPD profile of apocynin.
The distribution of the compounds between blood and brain is 
a very important criterion for potential drug candidate to exert de-
sired therapeutic effect in the CNS, or in contrary, not to cross BBB 
to avoid undesirable side effects. Previous study using in vitro BBB 
penetrating assay had shown that apocynin had a BBB permeability 
coefficient of 4.95 ± 0.39 cm/s, which was better than temozolo-
mide.28 In the current study, we found that apocynin displayed a sat-
isfactory	permeability	of	the	BBB	with	logBB	values	between	−0.04	
to 1. In addition, we also found that apocynin appeared to have a 
longer half-life in the brain than in the plasma. Further detailed in-
vestigation is needed to address the mechanism of apocynin to cross 
BBB and the involvement of uptake/ efflux transporter in the brain 
tissues. However, using three separate complementary techniques 
of ROS detection, that is, lucigenin-chemiluminescence, lipid perox-
idation, and DHE fluorescence on brain sections, we have demon-
strated clearly a time-dependent inhibitory effect of apocynin on 
brain ROS production.
Mouse is one of the mostly used species for experimental 
studies of human diseases. Our study had established an effective 
method for apocynin extraction and detection in mouse tissues. 
The dosing regimen and sampling times used in our study were ap-
propriate for apocynin PKPD characterization. Apocynin is a small 
molecule with pKa value of 8.17 and log P value (partitioning coef-
ficient in n-octanol/water) of .83, which give apocynin easy access 
to the cell membrane and its target sites.7	We	found	that	apocynin	
after iv injection displayed a short plasma terminal half-life and 
high clearance and kel, indicating that apocynin can be removed 
from blood at a high rate and distributed into peripheral organs.
It	 was	 reported	 previously	 that	 80%	 of	 the	 apocynin	 ad-
ministered by intraperitoneal injection in rats was recovered in 
unchanged form in urine samples collected at 20 hours after injec-
tion.26 Apocynin treatment has been found to raise the renal blood 
flow, glomerular filtration rate, increases creatine clearance and 
to protect kidney from cyclosporine A induced nephrotoxicity.29 
F I G U R E  6   Brain Nox2 expression detected by immunofluorescence. Nox2 was labelled by Cy3 (red) and nuclei were labeled with 
4′,6-diamidino-2-phenylindole4′,6-diamidino-2-phenylindole	(DAPI,	blue)	to	visualized	cells.	Nox2	fluorescence	intensities	were	quantified.	
*P < .05 for indicated values vs NCD values. †P < .05 for indicated values vs HFD values. n = 6 mice/group and at least three sections per 
mouse brain were used. Nox2, Nox2-containing NADPH oxidase
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In the current study, we found that apocynin has a high renal 
clearance, which is an advantage of apocynin to inhibit renal ox-
idative stress. However, in the case of renal failure and dysfunc-
tion, apocynin dose needs to be carefully adjusted. In agreement 
with a previous study,17 we found that apocynin PK values fit-
ted best into one compartment model. The crucial information of 
apocynin PKPD profile reported here can be used for prediction 
of apocynin plasma concentrations under different experimental 
conditions and help to design dosing regimen in clinical medicine. 
However, interspecies differences in drug metabolism and BBB 
should be considered for the application of our data.
HFD-induced mouse model of obesity and insulin resistance 
has been shown to display an accelerated aging phonotype and 
increased levels of oxidative stress/damage in organ function.30 
Therefore, it would be a good model for us to examine the therapeu-
tic potential of apocynin to inhibit organ oxidative stress associated 
with metabolic disorder and aging. Once again, we discovered that 
long-term oral application of apocynin (16 weeks in drinking water) 
reduced significantly HFD-induced major organ oxidative stress.
In conclusion, our study had characterised the PKPD profiles 
of apocynin as a Nox2 inhibitor both in vivo and in silico. Apocynin 
displayed a shot half-life, a rapid clearance from blood and effec-
tive distribution to major organs including the liver, heart, and 
brain. Apocynin inhibited the ROS production in major organs 
under HFD-induced diseased conditions. The crucial informa-
tion provided by the current study helps further development of 
apocynin as potential drug for the treatment of oxidative-stress 
related diseases.
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